Skip to main content
. 2019 Oct 18;37(35):3446–3454. doi: 10.1200/JCO.19.01367

FIG 3.

FIG 3.

Line graphs showing changes over time in plasma free (unbound) vascular endothelial growth factor (VEGF) for adult and pediatric participants. Anti-VEGF therapy with bevacizumab did not significantly decrease the plasma levels of free VEGF in participants with neurofibromatosis type 2. Vertical bars indicate interquartile range. (*) P < .05.